Cardiorentis Heart-Failure Study Pulled From Cardiology Meeting

  • Data wasn't ready for presentation, spokeswoman says
  • Swiss company hoped to use the findings to raise capital

Cardiorentis AG, a closely held Swiss pharmaceutical company, and researchers investigating its experimental drug to treat worsening heart failure won’t present their findings at the American College of Cardiology meeting on Monday as scheduled.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.